TherapeuticsMD, Inc.

As of September 8, 2025, TherapeuticsMD, Inc. shows a mildly bullish trend despite mixed technical indicators, having underperformed the S&P 500 recently but outperformed it year-to-date.

As of November 12, 2024, TherapeuticsMD, Inc. is considered a risky investment due to its overvaluation indicated by poor financial metrics, including a Price to Book Value of 0.54, an EV to Sales ratio of 5.29, and a P/E ratio of -12.50, alongside a troubling 1-year stock return of -34.94% compared to the S&P 500's 17.14%.

As of November 12, 2024, TherapeuticsMD, Inc. is rated as "risky" and overvalued, with key financial ratios indicating distress, a negative return of -42.19% over the past year, and a P/E ratio of -12.96, compared to peers ASP Isotopes, Inc. and Journey Medical Corp.

As of June 10, 2025, TherapeuticsMD, Inc. shows a mildly bearish trend due to daily moving averages, despite some bullish indicators on weekly and monthly charts, indicating a cautious outlook.

As of March 2022, the management team of TherapeuticsMD, Inc. includes Gov. Tommy Thompson (Independent Chairman), CEO Robert Finizio, and several independent directors: Paul Bisaro, J. Martin Carroll, Cooper Collins, Karen Ling, and Jules Musing. They oversee the company's strategic direction and operations.

TherapeuticsMD, Inc. is a women's healthcare company specializing in hormone therapy pharmaceutical products. It has a market cap of $12.96 million and reported net sales of $0 million with a net profit of -$1 million as of March 2025.

As of Jun 18, TherapeuticsMD, Inc. has a market capitalization of 12.96 million, categorizing it as a Micro Cap company, with net sales of 1.84 million and a net profit of -2.15 million over the latest four quarters. The company has shareholder's funds of 27.37 million and total assets of 38.82 million as of Dec 24.